ATRASENTAN HYDROCHLORIDE

ATRASENTAN HYDROCHLORIDE

Biochem/physiol Actions

Atrasentan is a selective endothelin ETA receptor antagonist with an IC50 of 0.2 nM for ETA compared to 190 nM for ETB receptors. It blocks blocks endothelin induced cell proliferation, and has been investigated as a possible treatment for prostate cancer, and more recently for therapy for diabetic kidney disease.

General description

Atrasentan has also been used to treat cardiovascular disease.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour InChI key InChI Manufacturer Solubility Form Assay Price Quantity
3575703 ATRASENTAN HYDROCHLORIDE white to beige IJFUJIFSUKPWCZ-SQMFDTLJSA-N 1S/C29H38N2O6.ClH/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20;/h8-13,16,23,27-28H,4-7,14 SIGMA-ALDRICH
£612.86 (exc VAT) per 25MG
-
+
3575704 ATRASENTAN HYDROCHLORIDE white to beige IJFUJIFSUKPWCZ-SQMFDTLJSA-N 1S/C29H38N2O6.ClH/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20;/h8-13,16,23,27-28H,4-7,14 SIGMA-ALDRICH
£178.29 (exc VAT) per 5MG
-
+